Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance*

Chuang, Yu-Chung, MD, PhD1,2; Lin, Hsin-Yi, PhD3; Chen, Pao-Yu, MD2; Lin, Chi-Ying, MD4; Chen, Yee-Chun, MD, PhD2; Wang, Jann-Tay, MD, PhD2; Chang, Shan-Chwen, MD, PhD2

doi: 10.1097/CCM.0000000000003264
Clinical Investigations

Objectives: Vancomycin-resistant enterococci are important pathogens for healthcare-associated infections. Although linezolid is bacteriostatic and daptomycin is rapidly bactericidal against vancomycin-resistant enterococci in vitro, it is not clear whether they differ in their effect on bacterial clearance in patients with vancomycin-resistant enterococci bloodstream infections.

Design: Prospective observational study.

Setting: Two university hospitals and research laboratory.

Patients: Patients with vancomycin-resistant enterococci bloodstream infection proven by blood cultures were prospectively enrolled from January 2010 to July 2015.

Interventions: Sequential blood samples were collected. Real-time quantitative polymerase chain reaction was used to monitor bacterial loads.

Measurements and Main Results: One hundred eight patients with vancomycin-resistant enterococci bloodstream infection were enrolled. Quantitative polymerase chain reaction assays were performed on 465 blood isolates. We found this method to be closely correlated with colony-forming units and more sensitive than culture. Sixty-three patients (58.3%) received “conventional dose” daptomycin (6–9 mg/kg), 15 (13.9%) received high-dose daptomycin (≥ 9 mg/kg), and 30 (27.8%) were treated with linezolid (600 mg every 12 hr) as sole agents. The initial mean bacterial load was 1.03 log10 copies/mL and unrelated to survival. Survivors had a more rapid early bacterial clearance than nonsurvivors (Δ log10 copies/mL/d; –0.16 vs 0.31; p = 0.02). Multivariable logistic regression showed that a slower early bacterial clearance independently predicted increased mortality (odds ratio, 3.21; 95% CI, 1.03–10.02; p = 0.045). Conventional dose daptomycin was associated with a significantly slower rate of bacterial clearance than high-dose daptomycin (Δ log10 copies/mL/d; –0.04 vs –0.41; p < 0.001) and linezolid (–0.04 vs –0.56; p = 0.043).

Conclusions: We found that survivors of vancomycin-resistant enterococci bloodstream infection had a significantly more rapid early bacterial clearance by quantitative polymerase chain reaction than nonsurvivors. High-dose daptomycin and linezolid were associated with more rapid bacterial clearance than conventional dose daptomycin. These results support recommendations that conventional dose daptomycin not be used for the treatment of patients with vancomycin-resistant enterococci bloodstream infection.

1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

2Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

3Department of Economics, National Chengchi University, Taipei, Taiwan.

4Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.

*See also p. 1700.

Drs. Wang and Chang contributed equally to this article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).

Supported partially by the Ministry of Science and Technology, Taiwan (104-2314-B-002-103-MY3, 104-2314-B-002-109-MY3, and 104-2410-H-004-009), the Ministry of Health and Welfare, Taiwan (MOHW107-TDU-B-211-113002), and National Taiwan University Hospital (NTUH.107-M3978).

Drs. Chuang, H.-Y. Lin, C.-Y. Lin, Y.-C. Chen, Wang, and Chang’s institutions received funding from the Ministry of Science and Technology, Taiwan. Dr. P.-Y. Chen has disclosed that he does not have any potential conflicts of interest.

For information regarding this article, E-mail: 14bcr@yahoo.com.tw

Copyright © by 2018 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.